title: Statin treatment before percutaneous cononary intervention.
abstract: Treatment with 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) improves short-and-long term prognosis in high-risk patients with stable coronary artery disease and in those with acute coronary syndrome and their use is strongly recommended for secondary prevention. Moreover, recent data suggest that statin pre-treatment is associated with a better short- and long-term outcome in patients undergoing percutaneous coronary intervention. Current guidelines for coronary revascularization recommend the use of high-dose of statins before percutaneous coronary intervention to reduce the risk of periprocedural myocardial infarction in statin naïve patients (class IIa A) and in those on chronic statin therapy (class IIa B). However, the beneficial clinical effects elicited by statins in patients undergoing coronary angioplasty may arise not only from a cardiac protection against periprocedural myocardial injury but also from a renal protection against acute kidney injury caused by iodinated contrast media. Actually, statins exert multiple non-lipid lowering (pleiotropic) effects, including improved endothelial function, reduced inflammatory and immuno-modulatory processes, oxidative stress and platelet adhesion, that may contribute to both cardio- and nephro-protection even in the short-term.
authors.affiliation: Cardiology Division of Prato Hospital, Prato, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Leoncini
authors.forename: Anna
authors.initials: A
authors.lastname: Toso
authors.forename: Mauro
authors.initials: M
authors.lastname: Maioli
authors.forename: Francesco
authors.initials: F
authors.lastname: Tropeano
authors.forename: Francesco
authors.initials: F
authors.lastname: Bellandi
keywords: Statins; kidney; myocardial infarction; percutaneous coronary intervention